HOME >> MEDICINE >> NEWS
New SSRI effective for the treatment of moderate-to-severe premature ejaculation

A selective serotonin reuptake inhibitor (SSRI) developed specifically for the treatment of premature ejaculation is safe and effective for men severely affected by the condition, according to an Article in this week's issue of The Lancet.

Premature ejaculation is the most common form of male sexual dysfunction, affecting 21-33% of men. Although the condition is highly undertreated, SSRIs, which were developed to treat depression and other psychiatric disorders, are being increasingly used as unlicensed treatments for premature ejaculation based on their side-effect of delayed ejaculation. However, these drugs can have drawbacks such as psychiatric problems, skin reactions, changes in bodyweight, and sexual side-effects like loss of libido.

In the study Jon Pryor (University of Minnesota, Minneapolis, MN, USA) and colleagues combined the results of two trials testing the effectiveness of dapoxetine, a short-acting SSRI developed specifically for the treatment of premature ejaculation. The analysis involved over 2600 men with moderate to severe premature ejaculation and their partners. Patients were randomly assigned to receive placebo (870), 30 mg dapoxetine (874), or 60 mg dapoxetine (870) and were instructed to take a dose 1-3 hours before sexual intercourse. On average, at the start of the study, the men ejaculated under a minute after penetration. The researchers found that after 12 weeks the time to ejaculation was 1.75 minutes for placebo, 2.78 minutes for 30 mg dapoxetine, and 3.32 minutes for 60 mg dapoxetine.

Dr Pryor adds: "Dapoxetine also improved patients' perceptions of control over ejaculation, satisfaction with sexual intercourse, and overall impression of change in condition. Partners benefited through improved satisfaction with sexual intercourse."

Common side-effects of the drug were nausea, diarrhoea, headache and dizziness.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
7-Sep-2006


Page: 1

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Osteoporosis screening and treatment may be cost-effective for selected older men
3. Study shows radiofrequency ablation highly effective in treating kidney tumors
4. New study examines effectiveness of tailored health messages
5. Scaling up HIV prevention programs is cost effective
6. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
7. U of M researchers assess effectiveness of computerized physician order entry system
8. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
9. Meningitis: effectiveness of preventive vaccination demonstrated
10. U-M study finds lymphoma drug effective over long term
11. Chemotherapy may enhance the effectiveness of brain tumor vaccines

Post Your Comments:
(Date:7/30/2015)... , ... July 30, 2015 , ... ... the ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill ... Chris Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and ...
(Date:7/30/2015)... ... , ... Using the latest online digital technologies, happiness expert Kay Walker is ... and manage major depression. , “Suicide is 100% preventable. The problem is the medical ... and die needlessly everyday,” says Walker. “I’m out to end suicide. Some may say ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web ... annual All-Stars Summit. Google Partners is the platform for search marketing agencies to ... support and tools necessary to run successful search marketing campaigns. Google Partners also ...
(Date:7/30/2015)... ... July 30, 2015 , ... Between 2012 and 2014 HIV infection rates ... Florida on June 17th. Those untreated heroin use disorders share their needles and ... of dirty needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2
(Date:7/30/2015)... BURLINGAME, Calif. , July 30, 2015 /PRNewswire/ ... Patent and Trademark Office has granted the company ... property covering Cleave,s lead molecule CB-5083. ... quinazolines as inhibitors of p97," U.S. 9,062,026, allows ... CB-5083, a first-in-class, highly selective oral inhibitor of ...
(Date:7/30/2015)... , July 30, 2015  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... quarter fiscal year 2015 financial results after the market ... call will follow on the same day at 4:30 ... President and Chief Executive Officer, and Rick Eiswirth ...
(Date:7/30/2015)...   HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the ... revenue of $73.6 million for the quarter ended ... the quarter ended June 30, 2014.  Currency fluctuations ... nine percentage points, during the three months ended ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
Cached News: